SAM
TCRT icon

Silvercrest Asset Management’s Alaunos Therapeutics TCRT Stock Holding History

Silvercrest Asset Management’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-133
Closed -$49K – 769
2020
Q1 		$49K Buy
+133
New +$68.8K ﹤0.01% 691

Other funds holding TCRT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Silvercrest Asset Management's TCRT Position: Q2 2020 in Review

Silvercrest Asset Management sold out of Alaunos Therapeutics (TCRT) in Q2 2020, closing a stake of 133 shares — an estimated $49K sold.

Silvercrest Asset Management first reported a position in TCRT in Q1 2020 and held it in 1 quarter. The position peaked at $49K in Q1 2020. 146 funds tracked by Wall St. Rank hold TCRT as of Q2 2020.

  • Silvercrest Asset Management reported no remaining Alaunos Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Silvercrest Asset Management sold 133 Alaunos Therapeutics shares in Q2 2020, an estimated $49K.
  • Silvercrest Asset Management first reported a position in Alaunos Therapeutics in Q1 2020 and held it in 1 quarter.
  • Silvercrest Asset Management's Alaunos Therapeutics position peaked at $49K in Q1 2020.
  • 146 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2020.

Based on Silvercrest Asset Management's 13F filing for Q2 2020, filed 14 Aug 2020.